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Abstract

Author Manuscript

Up to 90% of individuals with Huntington’s disease (HD), a progressive inherited
neurodegenerative disease, experience apathy. Apathy is particularly debilitating because it is
marked by a reduction in goal-directed behaviors, including self-care, social interactions, and
mobility. The objective of this study was to examine relationships among apathy, functional status,
physical function, cognitive function, behavioral status/emotional function, and health-related
quality of life. Clinician-rated measures of physical, cognitive and behavioral function, including
one clinician-rated item on apathy, and self-report measures of physical function, health-related
quality of life, emotional, cognitive, and social function were collected in a single session from
193 prodromal, 186 early stage manifest and 108 late stage manifest people with the HD mutation.
Multiple linear regression models were used to examine which outcomes best predicted clinicianrated apathy after controlling for disease stage. Greater apathy related to less independence,
increased motor impairment, and more clinician-rated behavioral problems (i.e. anger, irritability,
depression). Similarly, poorer self-reported health-related quality of life, greater chorea, greater
upper and lower extremity dysfunction, greater speech and swallowing dysfunction, worse anxiety,
depression and behavioral dyscontrol, worse cognitive function, and less satisfaction with social
roles related to greater apathy. In summary, apathy related to physical, cognitive and behavioral
dysfunction across disease stages. Future works should explore whether clinical interventions
targeting different functional domains may have the potential to reduce apathy in this population.

Author Manuscript
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Introduction

Author Manuscript

Huntington’s disease (HD) is a genetic, neurodegenerative disease characterized by motor,
cognitive and behavioral changes. The behavioral changes with HD are particularly
debilitating and relate to increased caregiver burden and reduced health-related quality of
life (HRQOL).1,2 Apathy is one of the most disabling behavioral symptoms for patients and
caregivers.3,4 Apathy affects up to 90% of individuals with HD4–6 and includes a marked
lack of motivation, as well as reduced goal-directed behavior and action initiation, including
self-care and mobility.7,8
Although the diagnosis for manifest HD relies heavily on motor manifestations, apathy may
either precede motor difficulties or occur early in the course of the disease,10,11 thereby
potentially providing an informative clinical marker of disease pathophysiology. Apathy
may predict disease onset,9 and it correlates negatively with age of disease onset,10 and
positively with the number of CAG repeats among those who are at risk for HD. Apathy
increased in pre-manifest individuals over a three-year period,9,11 suggesting that it may be
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useful for marking progression over time even prior to clinical diagnosis. In manifest
disease, higher levels of apathy independently predict disability12 and correlate with longer
disease duration,13 greater functional impairment14,15 and increased cognitive difficulty in
attention, set-shifting, memory and sequencing.16 Apathy also relates to depression3 and
irritability17 in HD, although its association to other behavioral symptoms remains to be
clarified. Given the link between apathy and disability, as well as the presence of apathy
across disease stages, apathy may be an important measure for tracking and monitoring
disease progression in both early and late stage of HD.

Author Manuscript

While evidence suggests that higher levels of apathy relate to poorer functional, motor,
cognitive and behavioral outcomes, as well as lower HRQOL in HD, a more comprehensive
analysis of these associations is needed. Evidence from other neurodegenerative disease
shows that apathy aligns with a greater caregiver burden, greater disability, and less
rehabilitation success.18 Additionally, apathy is linked to poorer cognitive performance on
executive function tasks, more severe motor impairments, and communication difficulties,19
factors that have not yet been examined in HD. A better understanding of the associations
among apathy and other measures in HD may provide insights into therapeutics or
rehabilitation strategies to target apathy, which is especially important given the lack of
existing recommendations or treatments for apathy. 20 Therefore, the objective of this study
was to examine associations among apathy, functional status, physical function, cognitive
function, behavioral status/emotional function and HRQOL. We hypothesized that apathy
would increase across disease stages, and that greater apathy would be related to worse
motor, cognitive and behavioral dysfunction and poorer HRQOL in persons with HD.

Methods
Author Manuscript

Data for the current analysis were collected from the baseline visit of a large cohort study
that examined HRQOL in individuals with prodromal (positive gene test but no clinical
diagnosis of HD), early- or late-stage HD (clinical diagnosis plus score of 7–13 for earlyand 0–6 for late-HD on the TFC [described below]).21 Data collection occurred in
conjunction with the PREDICT-HD study,22 a global cohort study with the purpose of
assessing early symptoms of HD in prodromal participants.
Participant Visits

Author Manuscript

Participants were recruited through eight established HD clinics (CA, IA, IN, MD, MI, MN,
MO, NJ), the National Research Roster for Huntington’s Disease, online medical record data
capture systems,23 and through articles/advertisements in HD-specific newsletters and
websites. Recruitment also included HD support groups and specialized nursing home units
throughout the US. Participants completed an in-person assessment, and a computer-based
self-report survey regarding HRQOL. Study visits lasted ~2 hours and participants were
provided $40 compensation. All data were collected in accordance with local institutional
review boards and participants provided informed consent prior to their participation in
study activities.
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Clinician-Rated Assessments

Author Manuscript

Functional Status: Three measures from the Unified Huntington Disease Rating Scale
(UHDRS) were administered to assess functional status: Total Functional Capacity (TFC),25
the Functional Assessment scale (FA), and the Independence Scale. The TFC25 provides a
clinician-rated assessment of ability to engage in work, manage finances, complete activities
of daily living (ADLs), complete chores, and live independently. Scores range from 0–13
with higher scores indicating better functioning. This measure was also used to determine
HD staging (criteria highlighted above). The FA consists of 25 yes/no questions that assess
the participant’s ability to perform tasks such as ADLs, engage in gainful employment,
manage finances, or complete chores. Total scores range from 0–25 with higher scores
indicating better functioning. The Independence Scale evaluates functional independence.
Scores range from 0–100 with higher scores indicating better independence. All functional
status measures were based on clinical interviews with the patient and an informant (when
possible).
Physical Limitations: The Total Motor Score (TMS) from the UHDRS was used to assess
motor impairment across 15 different domains, including chorea, dystonia, rigidity,
oculomotor function, and bradykinesia. Total scores range from 0–124 with higher scores
indicating more motor impairment.

Author Manuscript

Cognition: Three measures of cognition from the UHDRS were also administered: Verbal
Fluency, Symbol Digit Modalities Test (SDMT), and Stroop (Color Naming, Word Reading,
and Interference). Verbal Fluency provides a measure of executive function and language
and requires participants to name as many words as they can that start with a particular letter
within one minute. Scores reflect the total number of named words across three different
letters. The SDMT provides a measure of psychomotor processing speed, working memory,
and requires participants to match symbols with numbers according to a key that is provided
at the top of the page. Total scores reflect the number of correctly matched symbols provided
in 90 seconds. Scores range from 0 to 120 with higher scores indicating better psychomotor
processing speed. The Stroop is an executive functioning task that involves selective
attention, cognitive flexibility, cognitive inhibition and information processing speed. In this
three-part task, participants are required to name patches of colored ink (Color Naming),
read words (i.e., either red, green or blue; Word Reading), or name the color of written
words that are written in the wrong color ink (i.e., the word red written in green ink;
Interference). For each Stroop task, total scores reflect the number of correct responses
provided in 45 seconds; higher scores indicate better executive function.

Author Manuscript

Behavioral Status: The Problem Behaviors Assessment short form (PBAs)24 was
administered to evaluate eleven different behavioral problems and psychiatric symptoms
(depression, suicidal ideation, anxiety, anger/aggression, irritability, apathy, obsessive
compulsive behavior, perseverative thinking, delusions, hallucinations, and disoriented
behavior). Severity scores for each behavior are rated from 0 (normal) to 4 (causing
significant distress), while frequency scores are rated from 0 (never/almost never) to 4 (every
day/at least once a day). The product of severity and frequency scores are calculated to
J Neuropsychiatry Clin Neurosci. Author manuscript; available in PMC 2019 January 01.
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create a final score for each behavior which can range from 0 to 16, with higher scores
indicating worse behavioral problems for each domain. Total scores reflect sum of the scores
across all 11 behaviors, but given that apathy is our dependent variable of interest in the
current analysis, the total PBAs scores included only the other 10 behaviors.
Self-Report Measures
Generic Measures of HRQOL
EQ-5D.26: The EQ-5D is a standardized instrument that measures health status across five
domains of HRQOL: mobility, pain, ability to perform regular activities, ability to care for
oneself, and anxiety/depression. The EQ5D includes both an Index scores (which ranges
from 0 to 25 with higher scores indicating worse health outcomes) and a Health Scale score
(which ranges from 0 to 100, with lower scores indicating worse overall health).

Author Manuscript

RAND-12.27: The Rand-12 is a HRQOL measure that asks about limitations in activities in
relation to physical (pain, disability) and mental (depression, apathy, anxiety) health within
the past month. Separate scores are calculated for physical and mental sections of the
RAND-12, where raw scores range from 0 to 100. Final scores are calculated by subtracting
the participant’s score from the average for their age-group, resulting in positive and
negative difference scores.28 Positive scores reflect above average health for an individual’s
age group, while negative scores reflect below average health for the participant’s age group.
28

Author Manuscript

World Health Organization Disability Assessment Schedule 2.0 (WHODAS).29: The
WHODAS is a 12-item generic assessment of health and disability; it assesses mobility,
cognition, self-care, participation, and activities. Total scores range from 0 to 48, with higher
scores indicating more functional limitations.

Author Manuscript

Physical Ability Measures—Several physical ability measures from Quality of Life in
Neurological Disorders (Neuro-QoL)30 and the Huntington Disease Quality of Life
(HDQLIFE) measurement system21 were also completed. The Neuro-QoL is designed to
evaluate HRQOL in individuals with neurological conditions,30 whereas HDQLIFE was
developed to examine HRQOL domains specific to those living with HD. We administered
Neuro-QOL Lower Extremity Functioning (mobility), Neuro-QOL Upper Extremity
Functioning (ability to use hands and arms to perform tasks of ADL and fine motor
movements), HDQLIFE Speech Difficulties31 (the ability to speak and be understood in a
variety of social situations), HDQLIFE Swallowing Difficulties31 (the ability to swallow and
fears related to choking), and HDQLIFE Chorea32 (the effects of chorea on task
completion). Each item bank is scaled on a T-metric with a mean of 50 and a standard
deviation of 10 (the referent group for Neuro-QOL are other individuals with neurological
conditions, whereas the referent group for HDQLIFE are other individuals with HD), with
higher scores on Neuro-QoL domains indicating better functioning and high scores on
HDQLIFE measures indicating poorer physical functioning.
Emotional Status Measures—Study participants also completed several measures of
emotional function from Neuro-QoL,30 HDQLIFE,21 and the Patient Reported Outcomes
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Measurement Information System (PROMIS).33 Participants completed Neuro-QoL
Emotional/Behavioral Dyscontrol (irritability, impatience, and impulsiveness), Neuro-QoL
Positive Affect and Well-being (perceived sense of purpose and meaning), Neuro-QoL
Stigma (perceived negativity of others towards the participant as a result of their symptoms),
HDQLIFE Concern with Death and Dying34 (end of life issues including fear of death and
end of life planning), HDQLIFE Meaning and Purpose34 (sense of meaning and making the
most of the time they have left), PROMIS Anger, PROMIS Anxiety, and PROMIS
Depression. Similar to above, each item bank is scaled on a T-metric with a mean of 50 and
a standard deviation of 10 (the referent group for Neuro-QOL are other individuals with
neurological conditions, whereas the referent group for HDQLIFE are other individuals with
HD, and the referent group for PROMIS are individuals in the general population), with
higher scores indicating worse emotional functioning (except for Neuro-QoL Positive Affect
and Well-Being and HDQLIFE Meaning and Purpose, where higher scores indicate better
functioning).
Cognitive Ability Measures—Two measures of cognition were administered from
Neuro-QoL:30 Neuro-QoL Applied Cognition-Executive Function (cognitive planning and
organizing) and Neuro-QoL Applied-Cognition-General Concerns (perceived difficulty in
concentration and memory). Measures are scored on a T-metric with a mean of 50 and a
standard deviation of 10 (the referent group for these measures are other individuals with
neurological conditions), with higher scores indicating better cognitive function.

Author Manuscript

Social Function Measures—Two measures of social function were administered from
Neuro-QoL:30 Satisfaction with Social Roles and Activities (SATSRA; one’s contentment in
obligations pertaining to family, friends, and work) and Ability to Participate in Social Roles
and Activities (SRA; one’s involvement in obligations pertaining to family, friends, and
work). These item banks are scaled on a T-metric with a mean of 50 and a standard deviation
of 10 (the referent group are other individuals with neurological conditions), with higher
scores indicating better social function.
Statistical Analyses
Prior to examining the associations between clinician-rated and self-report variables and
PBAs Apathy scores, we first compared the levels of PBAs Apathy across the three staging
groups (prodromal, early- or late-stage HD) using one-way, two-tailed, analysis of variance.
Next, we computed a series of multiple linear regressions using PBAs Apathy as the
outcome and each of the clinician-rated and self-report variables as independent measures.

Author Manuscript

Clinician-Rated Apathy—A one-way two-tailed Analysis of Variance (ANOVA) was
conducted to determine differences in PBAs Apathy scores between the three HD staging
groups.
Creating Composite Scores—To minimize the number of regression models used,
composite scores for each of the nine aforementioned domains (clinician-rated physical
ability (TMS), clinician-rated functioning, clinician-rated cognition, clinician-rated
behavioral status, generic HRQOL, self-report physical ability, self-report emotional status,
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self-report cognition, and self-report social function) were created for participants with
complete data. Scores on each individual measure (i.e., Verbal Fluency, Stroop, and Symbol
Digits Modalities Test for clinician-rated cognition; UHDRS Independence scale, UHDRS
Functional Assessment, and UHDRS Total Functional Capacity for clinician-rated
functioning; the 11 behaviors on the PBAs for clinician-rated mental health; the UHDRS
Total Motor Scale for clinician-rated physical ability; Neuro-QoL Emotional and Behavioral
Dyscontrol, Neuro-QoL Positive Affect and Well-Being, Neuro-QoL Stigma, HDQLIFE
Concern with Death and Dying, HDQLIFE Meaning and Purpose, PROMIS Depression,
PROMIS Anxiety, and PROMIS Anger for self-reported emotional status; HDQLIFE
Chorea, HDQLIFE Speech Difficulties, HDQLIFE Swallowing Difficulties, Neuro-QoL
Lower Extremities, and Neuro-QoL Upper Extremities for self-reported physical ability;
Neuro-QoL Ability to Participate in Social Roles and Activities and Neuro-QoL Satisfaction
with Social Roles and Activities for social functioning; Neuro-QoL Executive Functioning
and Neuro-QoL General Concerns for self-reported cognition; the WHODAS, RAND-12,
and EQ-5D measures for generic HRQOL), were first recoded to ensure that higher scores
indicated better outcomes. Next, these individual scores were then standardized to have a
mean of 0 and standard deviation of 1. Then, these standardized scores were summed for
each respective composite score (i.e., clinician-rated cognition,, clinician-rated functioning,
clinician-rated behavioral status, self-report emotional status, and clinician-rated physical
ability, self-reported emotional status, self-report physical ability, self-report social function,
self-reported cognition, generic HRQOL). The sum scores within each of the nine composite
groups were then scaled with a mean of 0 and standard deviation of 1 so that each composite
score was on the same scale.

Author Manuscript

Multiple Linear Regression Models

Author Manuscript
Author Manuscript

Each of the nine composite scores were entered into separate multiple linear regression
models (two-tailed tests of significance at p<.05), where the composite measure was the
predictor, staging and clinician rated depression were covariates (except when depression
was included as part of the composite score [i.e., analysis examinging Clinician Mental
Health]), and apathy was the outcome. R2 values were used to determine which variables
accounted for the most variance in apathy scores. We considered R2 values between .01 and .
08 to be small or minimal effect sizes, values between .09 and .24 were considered
moderate, and effect sizes greater than .25 to be large. These R2 values were then compared
using Fisher’s R to Z transformation35, which sets correlation coefficient values onto a
normal distribution scale with confidence intervals that can be statistically evaluated (while
similar, this is not to be confused with the Fisher’s Z Distribution). Finally, the Root Mean
Square Error (RMSE), which is the standard deviation of the residuals, was calculated as an
additional assessment of model fit.

Results
One hundred and ninety-three (193) prodromal, 187 early-stage, and 91 late-stage manifest
HD participants were assessed (Table 1). The three groups differed by age (F[2, 468] = 43.3;
p<.0001), which was expected given the progressive nature of HD. The prodromal
participants were approximately 8 years younger than the early stage group and 13 years
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younger than the late stage group. The prodromal participants also had significantly more
years of education (F[2, 434]= 15.6; p<.0001) than both the early and late stage groups. The
groups did not significantly differ for gender (X2= 3.60; p=.17). The groups did significantly
differ for race (Fisher’s Exact p<.0001); the prodromal group did not include African
Americans, whereas the early and late stage groups did. The groups also differed for marital
status (Fisher’s Exact p<.0001); the prodromal group did not include any widowed
individuals, and had fewer divorced/separated individuals than the other two groups.
Across the three HD groups, average PBAs apathy score was 2.5 (SD=4.0). The prodromal
group had an average score of 1.4 (SD=2.9), which was significantly lower than both the
early-stage (mean=3.0; SD=4.1) and late-stage (mean=3.9; SD=5.0) group (F[2,468]=14.9;
p<.0001). Early and late-stage scores did not significantly differ. Therefore, all models were
adjusted for stage of disease.

Author Manuscript

Multiple Linear Regression Models
Table 2 highlights findings from the multiple linear regression models, after controlling for
HD disease stage. For clinician-rated assessments, better behavioral status (t[1]= −12.77; p<.
0001) was associated with better apathy scores (Table 2). There was no association between
apathy and clinician-rated cognition (t[1]= −0.85; p=.3955), clinician-rated functioning
(t[1]= −1.15; p=.2504), nor clinician-rated physical ability (t[1]=−0.86; p=.3928). The
adjusted R2 value for behavioral status was large at 0.30, while the adjusted R2 values for
physical ability, functioning, and cognition were all moderate (0.20, 0.14 and 0.18,
respectively).

Author Manuscript

For self-reported HRQOL, better scores on the generic composite measure (t[1]= −2.33; p=.
0201), emotional status (t[1]= −3.74; p<.0001), cognition (t[1]= −5.04; p<.0001), and social
functioning (t[1]= −6.25; p<.0001) were all significantly associated with better apathy
outcomes (Table 2). Self-reported physical ability (t[1]= −1.46; p=.1445) was not associated
with apathy. Adjusted R2 values for generic HRQOL (.21), physical ability (0.19), emotional
status (0.22), cognition (0.24) were moderate, and social function (0.26) had a large effect
size.
Comparisons of R2 Effect Sizes

Author Manuscript

The Fisher’s R to Z transformations revealed significant differences between R2 values for
each of the 8 composite measures. The composite score with the highest R2 value was
clinician-rated problem behaviors (R2=0.30; Table 2). The R2 value for clinician-rated
problem behaviors did not significantly differ from generic HRQOL (R2=0.21; z = 1.79; p=.
0735). The R2 value for clinician-rated problem behaviors was, however, significantly higher
than clinician-rated physical functioning (R2=0.20; z=2.03; p=.04), clinician rated
functioning (R2=0.14; z=2.99; p=.0028), clinician rated cognition (R2=0.18; z=2.18; p=.
0324), and self-reported physical functioning (R2=0.19; z=2.21; p=.0271).. Additionally,
self-reported social functioning (R2=0.26) had a higher adjusted R2 value than clinician
rated functioning (R2=0.14; z=2.26; p=.0238). Generic HRQOL, self-report emotion, and
self-reported cognition had similar adjusted R2 values with all other composite measures.
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Discussion
This study examined associations among apathy and functional status, physical ability,
cognition, behavioral status/emotional health and HRQOL in participants with prodromal
and manifest HD. As expected, apathy levels differed by stage of disease, with individuals in
the prodromal group demonstrating less apathy than participants in the early and late stage
groups. These findings support other research that suggests that apathy increases with HD
progression.10

Author Manuscript
Author Manuscript

In our cohort, worsened functional capacity and behavioral status were associated with
higher levels of apathy. In addition, apathy related to almost all self-reported assessments of
these same constructs, as well as with cognition. These findings are largely consistent with
the extant literature in HD, which indicates that greater apathy relates to lower functional
status and reduced independence14,15,36. Our findings are somewhat discrepant from other
research in HD, PD, and AD suggesting that increased apathy relates to worse objectively
measured cognitive function.16,19 While previous research shows correlations between
objective cognition and apathy, our study did not find such associations. One explanation for
this is that our study measured different domains of cognitive function than previous studies.
The cognitive measures used in this study (Stroop, Verbal Fluency, and SDMT) primarily
measure executive functioning, processing speed, attention, and language, whereas other
studies have utilized the Mini-Mental State Exam 19, which measures orientation,
registration, calculation, and recall or the Mattis Dementia Rating Scale16, which measures
initiation, construction, conceptualization, and memory. Therefore, it is possible that
different domains of objective cognition have different associations with apathy. Although
apathy did not correlate with objective assessments of cognition, there was a significant
association between apathy and self-reported cognitive function. One explanation for this
discrepancy is that subjective measures of memory and cognition are often stronger
indicators of overall emotional distress, rather than an objective evaluation of cognition.38
Additionally, anosognosia, or symptom unawareness, is common in HD and therefore may
play a role in this discrepancy; previous studies have shown that participants with greater
cognitive deficits are more likely underreport cognitive symptoms.39
Although little is known about the association between apathy and emotional and behavioral
status in HD, our results are consistent with prior work showing associations among apathy,
depression and irritability.3,17 In our cohort, clinician-rated behavioral problems, selfreported emotional problems/symptoms, and lower levels of positive affect/well-being and
feelings of meaning/purpose were all associated with higher levels of apathy.

Author Manuscript

With regard to HRQOL, greater apathy related to worse overall HRQOL, and less social
satisfaction and participation. Such findings support previous work in HD40,41 and PD.19
This study builds upon prior work by including five different measures of HRQOL in a large
cohort of individuals with HD across stages of disease.
To our knowledge, no existing clinical treatments have targeted the reduction of apathy. Our
results, however, identify associations of apathy, such as depression and behavioral
dyscontrol that may be manageable with pharmacological and non-pharmacological
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interventions. These results align with studies in PD and AD, suggesting that many
associations with apathy may be common among neurodegenerative conditions. As
depression and behavioral dyscontrol are quite common in HD, future work is needed to
determine if interventions that target these specific domains may vicariously reduce apathy
as a result.

Author Manuscript

Although this study highlights a number of important findings with regard to apathy in HD,
it is also important to acknowledge several study limitations. First, findings are based on a
convenience sample of individuals with HD, and thus may not represent the HD population
at large. Second, although apathy is considered a multidimensional construct,7,8 this study
utilized a single clinician-rated item of apathy and did not include a self-report measure of
apathy. Future work should include a more comprehensive assessment of apathy that
includes multiple aspects of motivation. In addition, participants completed the clinicianrated assessments and self-report measures within a two-week window and not necessarily
within the same session, weakening analyses focused on the associations between clinicianrated apathy and self-report assessments for some participants.
Conclusions
Our data suggest that apathy relates to functional status, physical function, self-report
cognitive function, behavioral status/emotional function, and HRQOL in HD. These findings
are consistent with work in other neurodegenerative diseases and suggest that clinical
interventions should consider targeting apathy, since it appears to be rather pervasive in
terms of affecting multiple aspects of functioning and HRQOL. In addition, future work
should focus on further characterizing the different aspects of apathy that have been
established in other neurological diseases.
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Demographics of the three staging groups
Variable

Prodromal (N=193)

Early (N=187)

Late (N=91)

All (N=471)

43.1 (12.1)

51.5 (12.8)

56.2 (10.4)

48.9 (13.1)

Female

64.8

55.6

57.1

59.7

Male

35.2

44.4

42.9

40.3

White

98.5

95.7

94.5

96.6

African American

0.0

1.6

5.5

1.7

Other

1.0

2.7

0.0

1.5

Not Provided

0.5

0.0

0.0

0.2

Not Hispanic or Latino

93.3

92.5

97.2

93.8

Hispanic or Latino

1.0

4.3

0.9

2.3

Not Provided

5.7

3.2

1.9

3.9

16.0 (2.8)

14.8 (2.8)

14.2 (2.6)

15.2 (2.9)

Single, Never Married

14.4

15.7

8.2

13.8

Married

69.5

56.2

67.1

63.8

Separated/Divorced

13.9

21.4

22.4

18.4

Widowed

0.0

2.8

2.3

1.6

Living with Partner

2.2

3.9

0.0

2.4

42.1 (2.5)

43.2 (3.9)

43.3 (2.8)

43.0 (3.4)

Age(Years)*
M (SD)
Gender (%)

Race (%)*

Author Manuscript

Ethnicity (%)

Education (# of years)*
M (SD)
Marital Status (%)*

Author Manuscript

CAG Repeats
M (SD)
Note.

*

indicates significant group differences.
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462
305
270
455
429
438
433
434
433

A. Clinician-rated Physical Functioning

B. Clinician-rated Functioning

C. Clinician-rated Cognition

D. Clinician-rated Behavioral Health

E. Generic HRQOL Measure

F. Self-Report Physical Function

G. Self-Report Emotion

H. Self-Report Cognition

I. Self-Report Social Function

0.26

0.24

0.22

0.19

0.21

0.30

0.18

0.14

0.20

Adjusted R2

p<.0001

p<.05

**

*

RMSE: Root Mean Square Error (smaller is better)

All predictors are standardized with a mean of 0 and SD of 1

N

3.52
3.47
3.42

−3.74*
−5.04**
−6.25**

3.49

−2.33**
3.62

3.33

−1.46

3.74

−12.69**

4.03

3.52

RMSE

−0.85

−1.15

−0.86

T-value

Author Manuscript

Variable

Author Manuscript

With Standardized Composite/Aggregate Scores

B<I

H = A–I

G = A–I

F<D

E = A–I

A, B, C, F < D

C<D

B < D, I

A<D

Significant Adjusted R2 Comparisons
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